Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1114 12 |
Ultima descărcare din IBN: 2023-07-04 13:54 |
SM ISO690:2012 BACINSCHI, Nicolae, GHICAVÂI, Victor, BALTAG, Natalia, BACINSCHI, Aurelia, MORNEALA, Elena. Realizări şi perspective în tratamentul diabetului zanarat tip . In: Analele Ştiinţifice ale USMF „N. Testemiţanu”, 2012, nr. 1(13), pp. 187-195. ISSN 1857-1719. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Analele Ştiinţifice ale USMF „N. Testemiţanu” | ||||||
Numărul 1(13) / 2012 / ISSN 1857-1719 | ||||||
|
||||||
Pag. 187-195 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
The realisations and perspectives in diabetes mellitus treatment
The rational selection of oral antidiabetics in diabetes mellitus treatment, type II is determined by the influence upon pathogenic way, prevention of insulinoresistance and insulin secretion insufficiency. With this purpose theare can be utilized sulphonylureics (glyclazide, glypizide, glymepiride etc.), biguanides (metphormine), meglytinedes (repaglynide, nateglynide, mitiglynide), thyazolidindiones (pioglytazone, balaglyztazone, rivoglitazone etc.), dual/pan PPAR modulators ( tesaglitazar, muraglitazar, aleglitazar, chiglitazar etc.), tetrazaharides (acarboze, vogliboze etc.), GLP-1 agonists (exenatide, exenatide LAR, liraglutide, albiglutide etc.), DPP-IV antagonists and blockers (sitaglypide, vildaglyptide, saxaglyptine, aloglyptine), amilines analogues (pramlintid), selective sodium glucose cotransporter-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin etc.), 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors (INCB13739), situins (resveratrol etc.), AMP-activated protein kinase (imeglimin etc.), glucokinase activators (piragliatin etc.), agonists D2-receptors (bromcriptine), bile acid sequestrants (coleselevam) etc.. |
||||||
|